147 related articles for article (PubMed ID: 27816370)
21. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Kim JJ; Ortendahl J; Goldie SJ
Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Human Papillomavirus Vaccination After Excisional Procedure for Cervical Intraepithelial Neoplasia: A Cost-Effectiveness Analysis.
Chaiken SR; Bruegl AS; Caughey AB; Emerson J; Munro EG
Obstet Gynecol; 2023 Apr; 141(4):756-763. PubMed ID: 36897145
[TBL] [Abstract][Full Text] [Related]
24. Stopping the HPV vaccine crisis in Japan: Quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making.
Kitano T
J Infect Chemother; 2020 Mar; 26(3):225-230. PubMed ID: 31607433
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
[TBL] [Abstract][Full Text] [Related]
26. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.
Coupé VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Int J Cancer; 2009 Feb; 124(4):970-8. PubMed ID: 19035448
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
28. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
29. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
30. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands.
Simons JJM; Vida N; Westra TA; Postma MJ
Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
35. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
[TBL] [Abstract][Full Text] [Related]
38. The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia.
Uusküla A; Müürsepp A; Kawai K; Raag M; Jürisson M; Pillsbury M
BMC Infect Dis; 2013 Jul; 13():304. PubMed ID: 23819789
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
